Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus-Reference-Cited by-同舟云学术

Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus

Published:2010-02 Issue:2 Volume:19 Page:123-131
ISSN:0906-6705
Container-title:Experimental Dermatology
language:en
Short-container-title:

Author:

Järvinen Tiina M.,Hellquist Anna,Koskenmies Sari,Einarsdottir Elisabet,Koskinen Lotta L. E.,Jeskanen Leila,Berglind Linda,Panelius Jaana,Hasan Taina,Ranki Annamari,Kere Juha,Saarialho-Kere Ulpu

Publisher

Wiley

Subject

Dermatology,Molecular Biology,Biochemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0625.2009.00982.x/fullpdf

Reference52 articles.

1. 1st International Conference on Cutaneous Lupus Erythematosus Dusseldorf, Germany, September 1-5, 2004;Kuhn;Autoimmun Rev,2005

2. Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies;Lee;Autoimmunity,2006

3. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings;Sontheimer;Autoimmun Rev,2005

4. Epidemiology and socioeconomic impact of skin disease in lupus erythematosus;Tebbe;Lupus,1997

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance;Cancers;2024-08-02

2. Genetic polymorphisms in genes involved in the type I interferon system (STAT4 and IRF5): association with Asian SLE patients;Clinical Rheumatology;2024-07-04

3. Discoid lupus erythematosus successfully treated with deucravacitinib;JAAD Case Reports;2024-07

4. Autoimmune Responses and Therapeutic Interventions for Systemic Lupus Erythematosus: A Comprehensive Review;Endocrine, Metabolic & Immune Disorders - Drug Targets;2024-04

5. Nano‐encapsulated anandamide reduces inflammatory cytokines in vitro and lesion severity in a murine model of cutaneous lupus erythematosus;Experimental Dermatology;2023-09-19